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Abstract
Introduction:  Sudden  deafness  is  characterized  by  an  abrupt  hearing  loss  of  at  least  30  dB  in
three sequential  frequencies  in  the  standard  pure  tone  audiogram  over  three  days  or  less.
Treatment  is  based  on  its  etiology,  and  oral  corticosteroids  are  widely  used.  Intratympanic
corticosteroids  are  included  as  primary  or  secondary  treatment  when  there  is  no  improvement
with the  use  of  oral  corticosteroids.
Objective:  To  determine  the  effectiveness  of  therapy  with  intratympanic  steroids  in  sudden
deafness.
Methods:  A  systematic  review  was  performed  of  publications  on  the  topic  in  the  databases  of
PubMed/MEDLINE,  with  the  keywords:  sudden  deafness,  sudden  hearing  loss,  and  corticoste-
roids.
Results: Thirty  scientiﬁc  studies  were  analyzed.  As  to  the  objectives  of  the  study  analyzed,
76.7% sought  to  evaluate  the  use  of  intratympanic  therapy  salvage  after  failure  to  conventional
treatment,  and  intratympanic  therapy  was  used  as  the  primary  treatment  23.3%  of  the  studies.
 Please cite this article as: Barreto MASC, Ledesma ALL, de Oliveira CACP, Bahmad Jr F. Intratympanic corticosteroid for sudden hearing
loss: does it really work? Braz J Otorhinolaryngol. 2016;82:353--64.
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Conclusion:  Intratympanic  corticosteroid  therapy  is  prescribed  primarily  when  there  is  failure
of conventional  therapy  and  when  it  is  limited  to  use  systemic  corticosteroids,  such  as  the
diabetic patient.
©  2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved.
PALAVRAS-CHAVE
Perda  súbita  da
audic¸ão;
Surdez  súbita;
Corticosteroides
Corticosteroide  intratimpânico  para  perda  súbita  da  audic¸ão:  isso  realmente
funciona?
Resumo
Introduc¸ão:  A  surdez  súbita  é  caracterizada  por  uma  perda  abrupta  da  audic¸ão  de  pelo  menos
30 dB  em  três  frequências  sequenciadas  no  audiograma  tonal  de  rotina  ao  longo  de  três  dias,  ou
menos. O  tratamento  é  fundamentado  em  sua  etiologia  e  corticosteroides  orais  são  amplamente
utilizados.  A  terapia  com  corticosteroide  intratimpânico  foi  incluída  como  tratamento  primário
ou secundário  nos  casos  em  que  não  houve  melhora  com  o  uso  de  corticosteroides  orais.
Objetivo:  Determinar  a  eﬁcácia  da  terapia  intratimpânica  com  esteroides  em  casos  de  surdez
súbita.
Método: Foi  realizada  uma  revisão  sistemática  das  publicac¸ões  sobre  o  tópico  no  banco  de
dados Pubmed/Medline,  com  as  palavras-chave:  surdez  súbita,  perda  súbita  da  audic¸ão  e  cor-
ticosteroides.
Resultados:  Foram  analisados  30  estudos  cientíﬁcos.  Com  relac¸ão  aos  objetivos  dos  estudos
analisados,  76,7%  procuravam  avaliar  o  uso  da  terapia  intratimpânica  em  seguida  ao  insucesso
com o  tratamento  convencional;  a  terapia  intratimpânica  foi  empregada  como  tratamento
primário em  23,3%  dos  estudos.
Conclusão:  A  terapia  com  corticosteroide  intratimpânico  é  prescrita  primariamente  nos  casos
de insucesso  com  a  terapia  convencional  e  quando  há  limitac¸ão  para  o  uso  de  corticosteroides
sistêmicos,  como  ocorre  com  o  paciente  diabético.
© 2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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These  treatments  for  sudden  hearing  loss  still  generatentroduction
udden  hearing  loss  (SHL)  was  ﬁrst  described  by  de  Kleyn  in
944  and  deﬁned  as  a  hearing  loss  of  at  least  30  dB  in  three
equential  frequencies  in  the  standard  pure  tone  audiogram
ver  three  days  or  less.1 It  may  be  characterized  as  an
mpairment  of  the  inner  ear  and/or  central  auditory  path-
ays,  with  variable  intensity  and  frequency,  ranging  from
ild  feeling  of  ear  being  clogged  to  total  loss  of  hearing.2,3
Although  it  is  thought  to  originate  mainly  from  viral,  vas-
ular,  or  immunologic  causes,  the  etiopathogenesis  of  the
isease  is  still  unknown,  so  the  disease  is  usually  referred
o  as  idiopathic  sudden  hearing  loss  (ISHL).  It  has  a  reported
ncidence  of  5--20  per  100,000  patients  per  year,  with  a  mean
f  50--60  years  and  no  predominance  of  sex.  In  most  cases,
here  is  unilateral  hearing  loss,  with  bilateral  involvement
eported  in  less  than  5%.1
Recovery  rate  in  untreated  patients  ranges  from  25%  to
0%,  mostly  resolving  within  two  weeks  of  onset  of  symp-
oms.  Although  the  methods  of  treatment  of  SHL  patients
ary  among  different  centers,  systemic  steroid  (SS)  therapy
s  the  most  commonly  used  modality  for  treatment  of  sudden
earing  loss.2
The  treatment  of  sudden  hearing  loss  is  based  on  its  etiol-
gy.  In  idiopathic  cases,  oral  corticosteroids  are  widely  used;
c
s
b
tntratympanic  steroids  have  been  trialed  in  patients  with
udden  hearing  loss,  because  they  provide  a  high  concen-
ration  in  the  labyrinth  in  animal  models,1 although  their
esults  are  conﬂicting.
There  are  several  advantages  of  intratympanic  treatment
Table  1):  (1)  the  procedure  is  well  tolerated  and  rela-
ively  easy  to  perform  as  an  outpatient  procedure  performed
nder  local  anesthesia  (topical);  (2)  general  anesthesia
an  be  avoided;  (3)  most  patients  understand  the  concept
f  intratympanic  therapy  and  easily  accept  the  proposed
herapy.4
Intratympanic  steroid  has  become  an  attractive  alter-
ative,  especially  in  cases  when  systemic  therapy  fails,  or
o  avoid  the  side  effects  of  the  systemic  use  of  steroids.
owever,  the  standardization  of  number  and  frequency  of
ntratympanic  treatments  and  drug  delivery  methods  remain
o  be  determined.5--7
In  2011,  Rauch  et  al.  conducted  a  multicenter,  ran-
omized  non-inferiority  trial  comparing  oral  corticosteroid
herapy  and  intratympanic  corticosteroid  therapy,  and  found
hat  the  two  treatment  methods  are  equally  effective.4onﬂicting  opinions  among  otolaryngologists.  In  certain
ituations,  such  as  sudden  hearing  loss  in  patients  with  dia-
etes,  intratympanic  corticosteroids  are  recommended  as
he  primary  treatment.5
Intratympanic  corticosteroid  for  sudden  hearing  loss  
Table  1  Advantages  of  intratympanic  treatment.
Advantages
Outpatient  procedure
Easily  administered
It  can  be  given  soon  after  diagnosis
Relatively  painless
Possible  use  in  patients  in  which  corticosteroids  are
contraindicated  (e.g.:  immune  suppression,  HIV,
tuberculosis,  diabetes)
High  drug  concentration  when  administered  directly
on the  affected  ear
Disadvantages/complications
Invasive  procedure
Tympanic  membrane  perforation
Pain
Otitis  media
s
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2Vertigo  (generally  temporary)
Hearing  loss
The  aim  of  this  study  was  to  present  the  effectiveness  of
intratympanic  corticosteroid  therapy  in  sudden  hearing  loss.
Methods
This  was  a  systematic  review  that  followed  the  precepts
of  the  Cochrane  Handbook  as  to  the  formulation  of  the
question,  location,  selection,  and  critical  evaluation  of  the
articles.  The  research  was  based  upon  the  question  ‘‘should
intratympanic  corticosteroid  therapy  be  indicated  for  sud-
den  deafness?’’  with  ‘sudden  deafness’  and  ‘sudden  hearing
loss’  associated  by  the  Boolean  AND  operator  to  ‘corticoste-
roids’.  All  descriptors  are  contained  in  the  vocabulary  and
PubMed/MEDLINE  using  as  strategy  the  descriptor  Medical
Subject  Heading  Terms  (MeSH).
The  type  of  study  and  English  language  were  considered
as  inclusion  criteria.  Thus,  articles  written  in  another  lan-
guage,  case  studies,  and  letters  to  the  editor  and  review
articles  were  excluded.
Abstracts  from  149  articles  were  assessed  by  two
reviewers,  who  pre-selected  for  analysis  those  correlated
descriptors  focusing  on  the  application  of  intratympanic  cor-
ticosteroid  in  isolation,  as  rescue  therapy,  or  in  combination.
A  total  of  30  items  had  tabular  data  containing  the
following  information:  author,  origin  and  year  of  publica-
tion,  journal,  sample  size  (n),  study  design,  description  of
intratympanic  corticosteroids  and  corticosteroid,  frequen-
cies  analyzed  in  pure  tone  audiometry,  and  results  of  studies
(Tables  2--5).
Results
Regarding  the  design  of  the  studies,  63.3%  were  prospective,
30%  and  6.7%  retrospective  prospective  and  retrospective.
Only  three  studies  (10%)  were  controlled  and  randomized.
Three  other  studies  (10%)  were  randomized  and  only  two
(5%)  were  controlled.
As  to  the  objectives  of  the  studies  analyzed,  76.7%  sought
to  evaluate  the  use  of  intratympanic  therapy  salvage  after
failure  of  conventional  treatment.  Treatment  therapy  with
i
i
t
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ystemic  steroids  was  considered  as  conventional  therapy;
2.2%  of  the  studies  used  oral  administration  and  47.8%,
ntravenous  administration.  Intratympanic  therapy  was  used
s  the  primary  treatment  23.3%  of  the  studies.
It  is  noteworthy  that  100%  of  the  studies  used  auditory
valuation  by  pure  tone  audiometry  as  a  method  of  check-
ng  the  effectiveness  of  the  therapy  chosen,  mainly  using  as
mprovement  criteria  20  dB  increase  in  the  mean  frequen-
ies  of  0.5,  1,  2,  and  4  kHz.  Of  these,  some  studies  included
valuation  through  speech  audiometry  and  impedance.
Analyzing  the  articles  published  on  sudden  hearing  loss
nd  use  of  intratympanic  corticosteroid  therapy,  the  data
howed  that  this  is  a promising  treatment  modality,  espe-
ially  for  cases  where  there  was  a  failure  in  the  conventional
reatment,  as  well  as  in  those  where  systemic  corticosteroid
herapy  is  contraindicated.
It  can  be  seen  that  in  most  of  the  analyzed  studies,
he  authors  made  three  intratympanic  corticosteroid  appli-
ations,  usually  every  other  day.  However,  dosages  were
ifferent,  ranging  from  one  to  ﬁve  applications.
Pure  tone  audiometry  was  the  audiological  test  used  in
ll  the  studies  analyzed.  However,  because  of  the  possibility
f  sudden  deafness  is  multifactorial  and  affects  the  inner
ar  and/or  auditory  pathways,  the  authors  suggest  testing
lectrophysiological  objectives  accompanying  a  patient.
The  study  by  Rauch  et  al.  in  2011  compared  the  non-
nferiority  in  the  two  therapeutic  approaches  for  sudden
eafness  (intratympanic  and  oral),  and  250  subjects  were
ollowed  for  a  period  of  six  months.  They  found  that  non-
nferiority  was  deﬁned  as  a  difference  of  less  than  10  dB
n  hearing  improvement  between  treatments.  In  the  group
reated  with  oral  prednisolone  (n  =  121),  the  pure  tone
verage  (PTA)  improved  30.7  dB  compared  to  the  group
eceiving  intratympanic  corticosteroid  therapy  (n  =  129),
ho  presented  improvement  of  28.7  dB.4 Similarly  to  these
uthors,  Dallan  et  al.,8 in  Italy,  also  followed  patients  for
ix  months.  However,  their  study  examined  the  efﬁcacy  of
ntratympanic  corticosteroid  therapy  after  failure  of  oral
herapy.
Other  researchers  followed-up  for  up  to  three  months,
nd  most  of  the  time,  during  only  one  month  after  starting
reatment  with  intratympanic  corticosteroid.
The  following  studies  are  presented  according  to  the  type
f  therapy  used.
alvage  therapy  after  failure  of  oral  steroids
lontke  et  al.  evaluated  23  patients  with  unilateral  severe
nd  profound  SHL  refractory  to  initial  systemic  therapy
nd  compared  them  with  a  control  group  (n  =  23)  who  did
ot  receive  salvage  treatment.  The  PTA  threshold  after
ntratympanic  salvage  treatment  showed  a  statistically  sig-
iﬁcant  improvement  of  15  dB  (7--24  dB).  The  local  therapy
roup  showed  a  signiﬁcantly  better  improvement  (mean
9  dB,  6--32  dB)  than  the  historical  control  group  (mean  5  dB,
--11  dB).9
In  2006,  Choung  et  al.  analyzed  the  effect  of
ntratympanic  dexametasone  (IT-DEX).  Hearing  was  assessed
mmediately  before  every  injection  and  at  one  week  after
herapy.  Hearing  improvement  was  deﬁned  as  more  than
0  dB  in  PTA  and  was  observed  in  13  (39.4%)  of  33  patients
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Table  2  Studies  emphasizing  salvage  therapy  failure  of  oral  steroids.
Author  and  origin  Journal  Study  design  Subjects  (n)  Therapy  Medication  and
IT dosage
Audiometry
frequency
(kHz)
Results  Effectiveness
rate  (%)
Plontke  et  al.,
2005
Germany
Acta  Otolaryngol  Retrospective,
placebo-controlled
clinical  trial
46:  23  (IT  post
OS),  23  (OS)
IT  post
OS  ×  OS
MET  40  mg/mL
DEX  4  mg/mL
0.5,  1,  2,  3  The  study  provided
strong  arguments  for  the
need  for  controlled
studies  to  investigate  the
efﬁcacy  of  IT  therapy.
(23)  95.0
(23)  25.0
Dallan et  al.,
2006
Italy
ORL  J
Otorhinolaryngol
Relat  Spec
Prospective  8  IT  post
OS  ×  OS
MET  40  mg/mL  0.5,  1,  2,  3  IT  is  safe  and  effective  in
cases  of  refractory  SHL.
(8)  75.0
Choung et  al.,
2006
Korea
Laryngoscope  Case--control,
prospective  and
retrospective
67:  33  (IT  post
OS),  34  (OS)
IT  post
OS  ×  OS
DEX  0.5,  1,  2,  4  IT  is  simple  and  effective
post  OS.
(33)  39.4
(34)  6.1
Raymundo et  al.,
2010
Brazil
Braz  J
Otorhinolaringol
Prospective  14  IT  post  OS  MET  40  mg/mL  0.5,  1,  2  IT  is  effective  in  patients
who  did  not  improve
with  OS  therapy.
(14)  71.4
Chen et  al.,  2010
China
J  Otolaryngol
Head  Neck  Surg
Prospective  36  (IT  post  OS)  IT  post  OS  MET  40  mg/mL  0.125,  0.25,
0.5,  1,  2,  4,  8
IT  is  effective  in  cases  of
SHL  or  contraindication.
(36)  34.2
She et  al.,  2010
China
Otolaryngol  Head
Neck  Surg
Prospective  49:  26  (IT)
23  (without
treatment)
IT  post  OS  MET  40  mg/mL  0.25,  0.5,  1,  2,
3, 4,  8
IT  through  microcatheter
is promising  for
refractory  SHL.
(26)  61.9
(23)  21.7
Moon et  al.,  2011
Korea
Otol  Neurotol  Retrospective  151:  59  (OS),
26 (OS  2
cycles),  66
(OS  +  IT)
IT  post  OS  DEX  0.4  at
0.5 mL
0.5,  1,  2,  3  IT  as  rescue  therapy  was
more  effective  than
another  dose  of  OS.
(59)  16.9
(26)  15.3
(66)  48.4
Lee et  al.,  2011
Korea
Eur  Archi
Otorhinolaryngol
Prospective,
case--control,
randomized
46:  21  (IT  post
OS),  25  (OS)
IT  post
OS  ×  OS
DEX  0.3  at
0.4 mL
0.5,  1,  2,  3  IT  is  simple  and  effective
post  OS.
(21)  47.6
(25)  16.0
Barreto et  al.,
2012
Brazil
Int  Tinnitus  J  Prospective  8  IT  post  OS  MET  0.5,  1,  2,  4  IT  was  effective  in  relief
of tinnitus.
(8)  25.0
Wang et  al.,  2012
China
J  Zhejiang  Univ
Sci  B
Clinical  trial,
nonrandomized,
retrospective
55  (IT),  32  (OS)  IT  post  OS  DEX  10  mg  0.5,  1,  2,  3,  4  IT  is  simple  and  effective
post  OS.
(55)  82.0
(32)  9.4
Chou et  al.,  2013
Taiwan
Laryngoscope  Case--control,
prospective  and
retrospective
60:  30  (IT),  30
transtympanic
IT  post  OS  0.5,  1,  2,  4  IT  had  better
audiological  results.
(30)  53.3
(30)  43.3
IT; intratympanic; IT post OS, intratympanic salvage therapy post oral steroid IT; OS, oral steroid.
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Table  3  Studies  emphasizing  salvage  therapy  after  failure  of  intravenous  steroids.
Author  and  origin Journal  Study  design Subjects  (n) Therapy  Medication  and
IT dosage
Audiometry
frequency  (kHz)
Results Effectiveness
rate  (%)
Kakehata  et  al.,
2006
Japan
Otol  Neurotol Prospective Diabetics
31:  10  (IT),  21  (IV)
IT  ×IV DEX  4  mg/mL 0.25,  0.5,  1,  2,  4 IT  is  as  effective  as
IV.
(10)  100.0
(21)  67.0
Xenellis et  al.,
2006
Greece
Otolaryngol  Head
Neck  Surg
Prospective 37:  19  (IT  post  IV),
18  (IV)
IT  post  IV MET  40  mg/mL 0.5,  1,  2,  4 IT  post  failure  IV  is
safe  and  effective
in cases  of
refractory  SHL.
(19)  47.0
(18)  0.0
Plaza and  Herráiz,
2007
Spain
Otolaryngol  Head
Neck  Surg
Prospective,
non-randomized
18:  9  (IT  post  IV),
9 (OS  post  IV)
IT  post  IV  MET  20  mg/mL  0.5,  1,  2,  3  IT  is  safe  and
effective  in  cases  of
refractory  SHL.
(9)  55
(9)  0.0
Plontke et  al.,
2009
Germany
Laryngoscope  Randomized,
double-blind,
placebo-
controlled,
multicenter
23  IT  post  IV  DEX  0.5,  1,  2,  4  IT  had  better
results.
(23)  24.4
Dallan et  al.,  2010
Italy
Otol  Neurotol  Retrospective  27  IT  post  IV  MET  40  mg/mL  0.5,  1,  2,  3  IT  is  effective  in
cases  of  refractory
SHL.
(27)  55
Li et  al.,  2011
China
Audiol  &
Neurotol
Prospective  65:  24  IT  post  IV,
21 topic  post  IV,
20 IV
IT  post  IV  MET  40  mg/mL  0.5,  1,  2,  4  IT  is  efﬁcient  rescue  (24)  37
(21)  0.0
(20)  0.0
IT, intratympanic; post-IV, intratympanic salvage therapy post intravenous steroid; OS, oral steroid; IV, intravenous steroid.
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Table  4  Studies  emphasizing  primary  therapy.
Author  and  origin  Journal  Study  design  Subjects  (n)  Therapy  Medication  and
IT  dosage
Audiometry
frequency  (kHz)
Results  Effectiveness
rate  (%)
Banerjee  and
Parmers,  2005
Canada
Otol  Neurotol  Retrospective  26  IT  MET  40  mg/mL  0.5,  1,  2  IT  is  safe  and
effective,  no
signiﬁcant  adverse
effects.
(26)  75.4
Filipo et  al.,  2010
Italy
Acta
Otolaryngol
Prospective  34  IT  P  62.5  mg/mL  0.5,  1,  2  IT  was  effective.  (34)  79.3
Rauch et  al.,  2011
USA
JAMA  Clinical  trial,
prospective,
randomized,
multicenter
250:  129  (IT)  IT  ×  OS  MET  40  mg/mL  0.5,  1,  2,  4  IT  can  be  used
when  there  is
contraindication
to  OS.
(129)  86.8
(121)  87.6
Kakehata et  al.,
2011
Japan
Audiol  &
Neurotol
Retrospective  76:  19  IT,  24  IT
post  OS,  33  OS
IT  ×  OS  ×  IT
post  OS
DEX  4  mg/mL  0.25,  0.5,  1,  2,  4  Short-term  IT  has
high  response  rate
and  healing,  and
can  be  used  as  a
ﬁrst  or  second
choice.
(19)  95.0
(24)  63.0
(33)  84.0
Zhang et  al.,  2012
China
Acta  Oto-
Laryngologica
Prospective  74:  35  IT,  39  IT
post  OS
IT  DEX  0.5  at
0.7  mL
0.25,  0.5,  1,  2,  4  IT  is  effective  as
ﬁrst  choice  and  as
rescue  therapy,
and  the
Eustachian  tube  is
a noninvasive  way
to  provide  safe
medication
administration.
(35)  80.0
(39)  64.1
Filipo et  al.,  2013
Italy
Laryngoscope  Prospective,
randomized,
triple-blind
50:  25  (IT),  25
(without
treatment)
IT  MET  40  mg/mL  0.25,  0.5,  1,  2,  3,
4,  8
IT  was  effective.  (25)  76.0
(25)  20.0
IT, intratympanic; IT post OS, intratympanic salvage therapy post oral steroid IT; OS, oral steroid.
Intratym
panic
 corticosteroid
 for
 sudden
 hearing
 loss
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Table  5  Studies  emphasizing  combination  therapy.
Author  and  origin Journal  Study  design Subjects  (n) Therapy  Medication  and
IT dosage
Audiometry
frequency  (kHz)
Results Effectiveness
rate  (%)
Lautermann
et  al.,  2005
Germany
Eur  Arch
Otorhinolaryn-
gol
Prospective,
nonrandomized
27:  14  (IV),  13
(IT +  IV)
IV  ×  IT  +  IV MET  32  mg/mL 0.5,  0.75,  1,  2,
3, 4
IT  did  not  increase
the  hearing  gain.
(14)  51.8
(13)  48.4
Gouveris et  al.,
2011
Germany
Otol  Neurotol Retrospective 170:  94  HL
moderate  (IV)
76  HL  severe
(IV+  IT)
IV  ×  IV  +  IT DEX  0.4  mL,
8  mg/mL
0.5,  1,  2,  4,  8 There  was  no
difference  between
the  groups.
(94)  70.0
(76)  73.0
Arslan et  al.,
2011
Turkey
Otol  Neurotol Prospective 128:  73
(IV  +  OS),  84
(IT  post  OS)
IT  post
OS  ×  IV  +  OS
MET  0.5  mL
125  mg/mL
0.5,  1,  2,  4 IT  as  rescue  therapy
increased  the
likelihood  of  hearing
recovery.
(73)  40.0
(84)  70.0
Bae et  al.,  2013
Korea
Acta  Oto-
Laryngologica
Retrospective 735:  94  (IT),
444  (OS),  197
(OS  +  IT)
IT  ×  OS  ×  IT  +  OS DEX  0.5  at
0.6 mL
0.5,  1,  2,  3 IT  was  as  effective  as
OS and  OS  +  IT  should
indicate  when  there
is a  contraindication
to  OS.
94  (64.9)
444  (68.7)
197  (59.3)
Koltsidopoulos
et al.,  2013
Greece
Otol  Neurotol  Prospective,
clinical  trial,
quasi-
randomized,
controlled
92
46
(IT  +  OS)  ×  46
(IV +  OS)
IT  +  OS  ×  IV  +  OS  DEX  0.4  at
0.6 mL
0.5,  1,  2,  4  IT  +  OS  were  more
effective  in  patients
with  moderate  to
severe  HL.
(46)  75.0
(46)  41.1
Baysal et  al.,
2013
Turkey
J  Craniofac
Surg
Retrospective  69:  30  (OS),
39  (OS  +  IT)
OS  +  IT
X
OS
DEX  0.5  mL  0.5,  1,  2,  4  There  was  no
difference  between
the  groups.
30  (74.3)
39  (77.4)
Gundogan et  al.,
2013
Turkey
Otolaringol
Head  Neck  Surg
Clinical  trial,
prospective,
randomized
73:  37
(IT  +  OS),  36
(OS)
OS  +  IT  ×  OS  MET  0.4  mL  0.5,  1,  2,  3  Combination  therapy
achieved  better
hearing  threshold  and
auditory
discrimination,  and
should  be  considered
as  initial  treatment.
(37)  89.0
(36)  61.1
IT, intratympanic; IT post OS, intratympanic salvage therapy post oral steroid IT; OS, oral steroid; IV, intravenous steroid.
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ho  underwent  IT-DEX,  and  in  two  (6.1%)  of  34  patients  in
he  control  group.10
In  2006,  Dallan  et  al.  sought  to  understand  the  real  efﬁ-
acy  of  transtympanic  steroid  therapy  for  SHL  in  patients  in
hom  traditional  therapies  had  failed.  A  solution  of  methyl-
rednisolone  (MP)  and  sodium  bicarbonate  was  administered
ia  transtympanic  injection  to  eight  patients.  Hearing  level
as  evaluated  before  therapy  and  at  days  one,  seven,
nd  30.  Hearing  improvement  was  obtained  in  75%  of  the
atients.8
In  2010,  Raymundo  et  al.  evaluated  14  patients  treated
ith  three  intratympanic  injections  of  methylprednisolone
IT-MP)  after  failing  treatment  with  systemic  steroids.
re-treatment  and  post-treatment  audiometric  evaluations
ncluding  PTA  at  frequencies  of  0.5,  1,  and  2  kHz,  and  speech
eception  thresholds  (SRT)  were  analyzed.  Ten  of  14  patients
resented  with  hearing  recovery  >20  dB  in  PTA  or  20  percent
n  SRT.5
In  2010,  Chen  et  al.  evaluated  the  effectiveness  of  IT-MP
n  36  patients  who  failed  routine  oral  steroid  therapy  and
wo  patients  with  a  contraindication  to  systemic  steroid,
ith  a  maximum  of  four  injections.  Hearing  level,  dizzi-
ess,  and  tinnitus  were  evaluated  before  the  ﬁrst  procedure
nd  20  days  after  the  last  injection.  Thirteen  of  38  patients
34.2%)  showed  an  improvement  in  hearing  levels.  The  aver-
ge  improvement  20  days  after  treatment  was  54  dB  in  the
earing  thresholds  of  0.125--8  kHz.11
In  2010,  She  et  al.  investigated  26  patients  in  the
tudy  group  (SG)  who  received  methylprednisolone  (MP)  for
en  days  and  the  conventional  treatment,  and  23  patients
ho  received  a  second  conventional  treatment  (no  steroid)
erved  as  the  comparison  group  (CG).  The  PTA  improvement
as  20.2  ±  15.6  dB  in  the  SG,  and  9.2  ±  13.7  dB  in  the  CG.  In
he  SG,  hearing  improvement  at  low  frequencies  was  better
han  that  at  high  frequencies.  The  data  suggested  that  the
reatment  may  be  more  effective  when  administered  at  the
arlier  stages  of  SHL  when  the  conventional  treatment  has
ailed.12
In  2011,  Moon  et  al.  investigated  the  therapeutic  efﬁ-
acy  of  IT-DEX  as  a  salvage  treatment  in  151  patients  who
ere  totally  unresponsive  two  weeks  after  treatment  initi-
tion.  The  151  refractory  patients  were  divided  into  three
roups:  those  receiving  no  further  treatment  (control  group,
 =  59),  those  receiving  one  more  ten  day  cycle  of  oral
teroids  (systemic  reapplication  group,  n  =  26),  and  those
eceiving  IT-DEX  therapy  (IT-DEX  group,  n  =  66).  Overall  hear-
ng  improvement  was  observed  in  ten  of  59  patients  in  the
ontrol  group,  in  four  of  26  in  the  systemic  reapplication
roup,  and  in  32  of  66  in  the  IT-DEX  group.  Analyzing  by  fre-
uency,  hearing  of  the  low  and  mid  frequencies  was  more
igniﬁcantly  improved  than  high  frequencies  in  the  IT-DEX
roup.13
In  2011,  Lee  et  al.  analyzed  patients  who  were  ran-
omly  classiﬁed  into  two  groups:  the  IT-DEX  group  (n  =  21)
eceived  four  sequential  IT-DEX  within  two  weeks  after  sys-
emic  steroids,  and  the  control  group  (n  =  25)  took  any  more
edications.  Hearing  improvement  was  deﬁned  as  a  10  dB
r  more  decrease  in  the  PTA  of  the  four  frequencies  (0.5,
,  2,  and  3  kHz).  Hearing  improvement  was  observed  in  ten
47.6%)  of  21  IT-DEX  patients  and  in  four  (16.0%)  of  25  control
atients.  The  improvement  of  the  mean  PTA  was  11.4  dB  in
he  IT-DEX  group  and  1.7  dB  in  the  control  group.  The  IT-DEX
i
w
aBarreto  MASC  et  al.
roup  showed  signiﬁcant  hearing  improvement  at  low  fre-
uency  (0.5  Hz)  compared  to  the  control  group.  The  patients
ith  ≥70  dB  in  PTA  before  IT-DEX  showed  signiﬁcant  hearing
mprovement  compared  to  the  other  patients  with  better
TAs.6
In  2012,  Barreto  et  al.  analyzed  the  effectiveness  of
ral  and  intratympanic  steroids  for  tinnitus  control  in  eight
atients  with  SHL  and  severe  disabling  tinnitus.  Hearing
valuation  and  application  of  the  Tinnitus  Handicap  Inven-
ory  and  visual  analogue  scale  were  performed  before  and
fter  treatment  of  sudden  deafness  with  oral  and  intratym-
anic  steroids.  Two  patients  showed  improvement  in  the
earing,  but  seven  showed  large  improvements  in  their
innitus,  which  was  demonstrated  by  an  improvement  in
he  values  of  the  degrees  of  severity  of  tinnitus.  Patients
ith  SHL  and  severe  disabling  tinnitus  who  underwent
ntratympanic  and  oral  corticosteroids  showed,  in  this  study,
igniﬁcant  reduction  and/or  remission  of  tinnitus.14
In  2012,  Wang  et  al.  observed  and  compared  the  efﬁcacy
f  IT-DEX  for  the  treatment  55  patients  with  refractory  SHL.
or  21  patients  (the  perfusion  group),  DEX  (2.5  mg/0.5  mL)
as  perfused  transtympanically  through  a  round  window
atheter,  using  an  infusion  pump  for  one  hour  twice  a  day  for
even  days,  giving  a  total  amount  of  35.0  mg.  For  23  patients
the  injection  group),  DEX  (2.5  mg/time)  was  injected  by
ympanic  membrane  puncture  at  intervals  of  two  days  on
 total  of  four  occasions,  giving  a  total  amount  of  10.0  mg.
or  11  patients  (the  drip  group),  DEX  (2.5  mg/0.5  mL)  was
ripped  via  a  ventilation  tube  placed  by  myringotomy,  once
n  the  ﬁrst  day  and  twice  a  day  for  the  remaining  six  days,
iving  a  total  amount  of  32.5  mg.  Thirty-two  patients  with
efractory  SHL  who  refused  to  undertake  further  treatments
ere  deﬁned  as  the  control  group.  Hearing  results  were
valuated  based  on  PTA  in  four  frequencies  (0.5,  1,  2,  and
 kHz).  The  improvements  in  mean  PTA  for  the  perfusion,
njection,  and  drip  groups  were  9.0,  8.6,  and  1.7  dB,  respec-
ively.  Hearing  improvement  was  signiﬁcantly  greater  in  the
erfusion  and  injection  groups  than  in  the  control  group
1.4  dB).  In  the  perfusion  group,  eight  out  of  21  patients
38.1%)  had  a  PTA  improvement  of  15--56  dB  (mean  29.8  dB);
n  the  injection  group,  eight  out  of  23  patients  (34.8%)  had
 PTA  improvement  of  16--54  dB  (mean  24.9  dB);  in  the  drip
roup,  one  of  11  patients  (9.1%)  had  a  PTA  improvement  of
6.0  dB;  in  the  control  group,  three  out  of  32  patients  (9.4%)
ad  a  PTA  improvement  of  15--36  dB  (mean  14.9  dB).15
In  2013,  Chou  et  al.  investigated  whether  near-continual
ranstympanic  steroid  perfusion  is  more  effective  than
ntermittent  intratympanic  steroid  injection  as  a  salvage
herapy  for  SHL  in  60  patients.  The  pre-salvage  pure  tone
hreshold  was  65.4  ±  13.5  dB  in  the  transtympanic  steroid
erfusion  group.  After  the  therapy,  the  hearing  threshold
as  improved  by  an  average  of  15.0  ±  9.7  dB,  and  53.3%  of
ubjects  had  improved  by  10  dB  or  more.  The  speech  dis-
rimination  score  (SDS)  was  improved  from  12.6  ±  7.0%  to
4.4  ±  6.4%.  In  the  intratympanic  steroid  injection  group,
he  pre-salvage  pure  tone  threshold  was  68.8  ±  16.0  dB.
fter  the  therapy,  the  hearing  threshold  was  improved  by
n  average  of  10.7  ±  9.8  dB,  and  43.3%  of  subjects  had
mproved  by  10  dB  or  more.  The  speech  discrimination  score
as  improved  from  13.3  ±  6.0%  to  46.4  ±  12%.16
Topical  intratympanic  injection  may  be  considered  as
 substitute  for  systemic  administration  in  patients  with
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aIntratympanic  corticosteroid  for  sudden  hearing  loss  
refractory  SHL,  especially  those  who  have  contraindications
to  systemic  steroid  administration.
Salvage  therapy  after  failure  of  intravenous
steroids
In  2006,  Xenellis  et  al.  analyzed  37  patients  with  SHL  who,
at  the  end  of  ten  days  of  therapy  with  intravenous  steroids
as  a  ﬁrst  line  treatment,  had  four  frequency  PTA  (0.5,  1,
2,  and  4  kHz)  and  were  randomized  into  two  groups:  treat-
ment  and  control.  Nineteen  patients  of  the  treatment  group
received  approximately  0.5  mL  sterile  aqueous  suspension
of  MP  in  a  concentration  of  80  mg/2  mL  by  direct  injec-
tion.  The  procedure  was  carried  out  four  times,  and  an
audiogram  was  performed  before  each  injection  and  approx-
imately  1.5  months  after  the  last  session.  With  regard  to
the  19  patients  who  received  intratympanic  treatment  (IT),
in  nine  patients,  the  PTA  threshold  improved  more  than
10  dB,  in  ten  patients  there  was  no  change  greater  than
10  dB,  and  no  patients  deteriorated  more  than  10  dB.  In
the  control  group,  none  of  the  patients  showed  any  change
greater  than  10  dB.  The  difference  was  statistically  signiﬁ-
cant.  The  treatment  group  showed  an  improvement  in  mean
PTA  of  14.9  dB,  whereas  the  control  group  showed  a  deteri-
oration  of  0.8  dB,  and  this  difference  also  was  statistically
signiﬁcant.17
In  2006,  Kakehata  et  al.  evaluated  the  efﬁcacy  of  IT-DEX
treatment  on  SHL  patients  with  diabetes  by  comparing  the
results  with  intravenous  administration  of  dexamethasone
(IV-DEX)  treatment.  In  the  IT-DEX  group  (n  =  10,  4  mg/mL  for
eight  days)  the  average  hearing  level  before  the  treatment
was  79  dB.  Overall,  all  ten  patients  showed  improvement
of  more  than  10  dB  in  the  PTA,  with  a  mean  improvement  of
41  dB.  Seven  patients  (70%)  demonstrated  successful  results,
and  four  recovered  completely.  In  the  IV-DEX  group  (n  =  21,
8  mg/d  for  ten  days),  14  (67%)  showed  improvement  of  more
than  10  dB,  with  a  mean  improvement  of  25  dB.  Thirty-
three  patients  (62%)  demonstrated  successful  results.  IT-DEX
treatment  is  at  least  as  effective  as  IV-DEX  treatment  for  SHL
patients  with  diabetes.18
In  2007,  Plaza  and  Herráiz  described  their  experience
with  50  patients  presenting  with  idiopathic  SHL,  treated
intravenously  over  ﬁve  days.  After  this  period,  patients
with  treatment  failure  (18  cases)  were  offered  intratym-
panic  steroid  treatment.  Nine  patients  refused,  whereas  the
other  nine  patients  received  three  weekly  injections  of  MP.
Recovery  of  hearing  was  reported  as  improvement  of  more
than  15  dB  in  PTA.  Intratympanic  steroid  treatment  improved
hearing  loss  in  ﬁve  patients  (55%).19
In  2009,  Plontke  et  al.  studied  the  safety  and  efﬁcacy
of  continuous  IT-DEX  in  patients  with  SHL  and  insuf-
ﬁcient  recovery  (mean  four  PTA  =  97  dB)  after  systemic
high-dose  glucocorticoid  therapy,  who  received  either  IT-
DEX  (4  mg/mL)  or  placebo  (NaCl  0.9%)  continuously  applied
for  14  days.  Intention-to-treat  analysis  for  the  primary  out-
come  criterion  (four  PTA:  0.5,  1,  2,  3  kHz)  during  the  placebo
controlled  study  period  (14  days)  showed  an  average  hearing
improvement  in  the  treatment  group  of  13.9  dB  and  in  the
placebo  group  of  5.4  dB.  Of  the  secondary  outcome  param-
eters,  the  largest  beneﬁt  of  local  salvage  therapy  was  found
for  maximum  speech  discrimination,  with  an  improvement
f
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f  24.4%  in  the  treatment  and  4.5%  in  the  placebo  group.
fter  a  three-month  follow-up  period,  hearing  improvement
n  the  two  groups  was  very  similar.20
In  2010,  Dallan  et  al.  analyzed  27  patients  unrespon-
ive  to  traditional  systemic  therapy  who  were  treated  with
ntratympanic  steroids.  The  mean  PTA  before  intratympanic
reatment  was  79.9  ±  21.4  dB;  at  day  30,  after  local  steroid
dministration,  the  mean  PTA  was  60.6  ±  24.9  dB.  Fifteen
55%)  of  27  patients  presented  a  ‘‘useful’’  improvement  in
he  hearing  status,  to  conﬁrm  the  usefulness  (at  least  50%  of
atients)  of  local  steroids  administration  in  cases  of  refrac-
ory  SHL.21
In  2011,  Li  et  al.  followed  65  patients  with  SHL  who  did
ot  respond  to  IV  treatment  with  prednisolone,  randomized
nto  three  groups:  treatment  with  IT  steroid,  treatment  with
teroid  in  ear  drops,  and  a  control  group.  The  24  patients
n  the  IT  group  received  IT-MET,  and  the  21  patients  in  the
ardrop  group  received  IT-MET  that  was  directly  dropped
nto  the  tympanic  membrane  through  the  ear  canal.  In  the
T  treatment  group,  audiogram  results  showed  that  the  PTA
or  speech  frequencies  (0.5,  1,  2,  and  4  kHz)  was  52.9  dB  at
he  end  of  systemic  treatment,  and  64.8  dB  at  the  end  of
T  treatment.  The  improvement  in  the  IT  group  was  signif-
cantly  better  than  that  in  the  other  two  groups,  with  37%
f  the  IT  patients  demonstrating  signiﬁcant  improvement  in
heir  hearing.22
IT  steroid  administration  after  failed  intravenous  steroids
s  a  safe  and  effective  treatment  in  sudden  hearing  loss.
rimary  therapy
n  2005,  Banerjee  and  Parners  determined  whether  instilla-
ion  of  intratympanic  steroids  (methylprednisolone  and/or
examethasone)  is  effective  in  the  treatment  of  SHL.  Pre-
reatment  and  post-treatment  of  26  patients’  PTA  and
DS  were  compared.  Overall,  there  was  a  27.2  ±  5.7  dB
mprovement  in  the  pure  tone  thresholds  and  a  25.4%  ±  6.2%
mprovement  in  SDS.23
In  2010,  Filipo  et  al.  evaluated  the  overall  success
ate,  morbidity,  and  prognostic  factors  of  a protocol  of
ntratympanic  steroid  administration  as  a  means  of  pri-
ary  therapy  for  SHL.  34  patients  were  treated  once  a
ay  for  three  consecutive  days  with  a  single  intratym-
anic  injection  of  prednisone  diluted  in  saline  solution.
mong  them,  16  patients  (47%)  reported  complete  recovery,
ith  a  PTA  that  returned  within  25  dB;  11  patients  (32.3%)
howed  improvement  in  hearing  of  more  than  30  dB,  and
our  patients  presented  improvement  in  PTA  between  10  and
0  dB.24
In  2011,  the  clinical  study  by  Rauch  et  al.  from  Harvard
niversity  was  a  scientiﬁc  milestone  because  of  the  num-
er  of  monitored  patients  (n  =  250).  It  was  a  multicentric
tudy,  including  16  research  centers  and  universities  in  North
merica  and  comparing  the  efﬁcacy  of  two  therapeutic
ethods  for  unilateral  SHL,  namely,  intratympanic  cortico-
teroids  as  a  ﬁrst-line  treatment  and  oral  corticosteroids,
lso  as  a  ﬁrst-line  treatment.  The  patients  were  followed
or  six  months.  One  hundred  twenty-nine  patients  received
our  doses  of  MET  40  mg/mL  and  121  patients  received  oral
rednisolone  60  mg/day.  The  results  demonstrated  no  sta-
istically  signiﬁcant  difference  when  comparing  the  two
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p62  
reatment  methods.  These  ﬁndings  could  be  obtained  after
nalyzing  the  audiological  results  by  pure  tone  audiometry,
nalyzing  means  in  the  frequencies  0.5  Hz,  1,  2,  and  4  kHz.4
In  2011,  Kakehata  et  al.  evaluated  the  efﬁcacy  of  daily
hort-term  IT-DEX  treatment  alone  in  76  SHL  patients  for
nitial  and/or  salvage  treatment.  The  average  hearing  level
as  determined  by  ﬁve  frequencies  (0.25,  0.5,  1,  2,  and
 kHz).  19  out  of  76  patients  ﬁt  the  criteria  for  initial  treat-
ent  in  the  study  (group  I),  while  24  patients,  who  had  failed
ystemic  therapy,  received  salvage  treatment  (group  S).  In
roup  I,  18  of  the  19  patients  (95%)  showed  improvement
f  more  than  10  dB  in  the  PTA,  with  a  mean  improve-
ent  of  40  dB.  20  patients  (63%)  recovered  completely  and
6  patients  (84%)  demonstrated  successful  results,  with  an
mprovement  of  more  than  30  dB.  In  group  S,  14  of  the  24
atients  (58%)  showed  improvement  of  16  dB  and  two  (8%)  of
he  seven  patients  (29%)  with  successful  results  recovered
ompletely.  Daily  short-term  IT-DEX  administration  using
AM  for  SHL  patients  without  concurrent  therapy  showed
 high  response  rate  and  high  cure  rate,  and  proved  to
e  an  alternative  therapeutic  option  to  high-dose  systemic
teroids  as  a  ﬁrst-  and/or  second-line  treatment.7
In  2012,  Zhang  et  al.  investigated  the  effectiveness
nd  safety  of  noninvasive  IT-DEX  perfusion  through  the
ustachian  tube  in  74  patients  with  SHL.  35  patients  met
he  criteria  for  initial  treatment  in  the  study  (Group  I),
hile  39  patients,  who  had  failed  systemic  therapy,  received
alvage  treatment  (Group  S).  IT-DEX  perfusion  through  the
ustachian  tube  was  applied  four  times  at  two-day  intervals.
ure  tone  test  and  tympanometry  were  performed  before
tarting  treatment,  and  24  h  and  one  week  afterwards.  With
egard  to  the  74  patients  who  received  IT,  80.0%  (28  of  35)  of
he  patients  in  Group  I  and  64.1%  (25  of  39)  patients  in  Group
 had  improvement  in  their  hearing  ability.  Noninvasive  IT-
EX  perfusion  through  the  Eustachian  tube  is  an  effective
nd  safe  therapy  in  cases  of  SHL.25
In  2013,  Filipo  et  al.  investigated  50  patients  affected
y  moderate  SHL,  involving  all  frequencies  from  250  Hz  to
 kHz  (a  ﬂat  audiogram).  Patients  were  randomized  into  two
roups  of  25  each.  The  ﬁrst  group  (intratympanic  steroid)
nderwent  a  daily  intratympanic  administration  of  pred-
isolone  for  three  consecutive  days.  The  second  group
control)  received  a  daily  intratympanic  injection  of  a  saline
olution  for  three  consecutive  days.  Audiometric  tests  were
erformed  at  day  seven  after  the  beginning  of  therapy  (T1),
nd  then  10  and  30  days  after  T1.  The  patients  in  both
roups  who  did  not  show  a  complete  recovery  at  T1  were
reated  with  oral  prednisone  at  a  tapering  dose.  In  the
ntratympanic  steroid  group,  19  out  of  25  patients  presented
omplete  recovery  at  T1  (76%),  whereas  in  the  control
roup,  the  number  of  patients  who  recovered  completely
t  T1  was  ﬁve  out  of  25  (20%).  The  PTA  recorded  at  T1
emonstrated  a  statistically  signiﬁcant  improvement  in  the
earing  threshold  of  the  ﬁrst  group  compared  to  the  control
roup.  The  mean  PTA  recorded  after  the  ﬁrst-line  treatment
T1)  demonstrated  a  signiﬁcant  therapeutic  action  of  the
hort-duration  intratympanic  steroid  therapy  on  moderate
HL,  with  a  ﬂat  audiogram  shape,  compared  to  the  natural
ourse  of  the  disease  and  the  placebo  effect  at  that  time
oint.26
IT  is  safe,  effective,  without  signiﬁcant  adverse  effects,
nd  can  be  used  as  a  ﬁrst  or  second  choice.
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ombination  therapy
n  2005,  Lautermann  et  al.  analyzed  27  patients  with  pro-
ound  SHL.  Fourteen  were  treated  with  a rheologic  infusion
herapy  consisting  of  systemic  prednisolone,  and  13  were
reated  additionally  with  methylprednisolone  transtympan-
cally  through  a ventilation  tube.  In  the  ﬁrst  group,  three
atients  had  good  recovery  of  hearing.  Another  ﬁve  patients
ad  a  partial  recovery.  The  average  hearing  gain  from  0.5,
.75,  1,  2,  3,  and  4  kHz  was  15  dB.  In  the  group  of  patients
ho  were  treated  additionally  with  local  corticoids,  two
eported  a good  recovery  of  hearing  and  another  two  only
ad  a  partial  recovery.  The  additional  transtympanic  appli-
ation  of  corticoids  did  not  result  in  a signiﬁcantly  improved
ecovery  of  hearing  in  comparison  to  the  patients  treated
ith  the  standard  therapy  alone.
In  2011,  Gouveris  et  al.  evaluated  the  differences
n  effectiveness  between  SHL  patients  treated  with
ntravenous  therapy  alone  and  patients  treated  with  a
ombination  of  intravenous  and  intratympanic  therapy.
inety-four  patients  with  moderate  SHL  were  treated  with
n  intravenous  steroid  and  vasoactive  regimen,  and  76
atients  with  severe  SHL  were  treated  with  a  combination
egimen  of  intravenous  and  intratympanic  therapy.  In  the
atter  group,  a  series  of  three  IT-DEX  were  applied  every  two
ays.  PTA  at  0.5,  1,  2,  4,  and  8  kHz  were  compared  between
roups.  The  combination  therapy  in  severe  SHL  did  not  show
ny  statistically  signiﬁcant  difference  in  effectiveness  com-
ared  to  intravenous  therapy  in  moderate  SHL.  In  patients
ith  severe  SHL,  starting  intratympanic  steroid  therapy  as
n  adjunct  early  in  the  course  of  intravenous  steroid  and
asoactive  therapy  improved  hearing  to  a  level  which  is
btained  in  patients  with  less  severe  (moderate)  SHL  treated
ith  intravenous  therapy  alone.27
In  2011,  Arslan  et  al.  compared  hearing  results  in  SHL  in
58  patients  treated  with  systemic  steroids  alone,  or  com-
ined  intratympanic  and  steroids.  Seventy-three  patients  in
he  systemic  therapy  group  received  consecutive  adminis-
ration  of  100  mg  intravenous  methylprednisolone  in  the  ﬁrst
ay,  then  80  mg/day  oral  prednisolone  in  three  divided  doses
or  the  next  two  days,  and  continued  with  oral  administra-
ion  of  steroids  by  tapering  the  dose  20  mg  in  every  two
ays.  Eighty-ﬁve  patients  in  the  combined  treatment  group
eceived  intratympanic  injection  of  methylprednisolone  (an
pproximate  dose  of  0.5  mL  at  125  mg/mL).  A  total  of  ﬁve
njections  on  alternate  days  were  performed.  The  mean  and
edian  PTA  gains  of  systemic  corticosteroid  therapy  (SCT)
roup  were  7.5  and  5  dB  at  ﬁfth  day,  12.1  and  7.5  dB  at
enth  day,  and  13.0  and  8.8  dB  at  15th  day.  The  mean  and
edian  PTA  gains  for  combined  treatment  (CT)  group  were
2.5  and  7.5  dB,  17.8  and  13.8  dB,  and  21.8  and  20.0  dB,
espectively.  Both  the  mean  and  the  median  PTA  gains  were
igniﬁcantly  different  between  the  SCT  and  CT  groups,  and
dding  intratympanic  methylprednisolone  to  systemic  ther-
py  increased  the  probability  of  hearing  recovery  in  patients
ith  SHL.28
In  2013,  Baysal  et  al.  evaluated  the  effectiveness  of  30
atients  using  oral  steroid  treatment  vs.  39  patients  using
ombined  oral  and  IT-DEX  for  SHL.  The  comparison  of  the
nitial  PTA  threshold  results  revealed  a  signiﬁcant  difference
etween  the  systemic  steroid  (SS)  group  and  the  systemic
nd  IT  steroid  group.  The  initial  PTA  was  74.33  dB  in  the  SS
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group  and  87.49  dB  in  the  IT  steroid  group.  The  difference  in
the  initial  PTA  results  was  signiﬁcant  between  the  SS  group
and  IT  steroid  group.  The  pure  tone  gain  in  the  SS  group  was
20.97  dB,  and  that  of  the  group  treated  with  both  systemic
and  IT  steroids  was  19.36  dB.  In  SHL,  the  administration  of
IT  steroids  in  conjunction  with  SS  therapy  appears  to  have
the  same  effect  on  the  restoration  of  hearing  as  the  effect
obtained  using  SS  therapy  alone.29
In  2013,  Gundogan  et  al.  compared  the  efﬁcacy  of  SS
alone  and  combined  with  IT-MET  in  the  treatment  of  73
patients.  The  patients  were  randomly  divided  into  two
groups  according  to  treatment:  group  A  (n  =  37)  received
combination  therapy  (intratympanic  methylprednisolone
and  oral  steroid)  and  group  B  (n  =  36)  received  oral  steroid
alone.  Group  A  demonstrated  signiﬁcant  hearing  improve-
ment  and  SDS  compared  with  the  use  of  SS  alone.  In  hearing
outcomes  in  patients  with  severe  hearing  loss,  combination
therapy  showed  statistically  signiﬁcant  hearing  improve-
ment  compared  with  oral  steroid  alone,  and  combination
therapy  can  be  considered  as  an  initial  treatment,  especially
for  patients  with  severe  hearing  loss.30
In  2013,  Koltsidopoulos  et  al.  investigated  the  therapeu-
tic  efﬁcacy  of  IT-DEX  combined  with  systemic  prednisolone
in  92  patients  allocated  into  two  groups.  The  control  group
was  treated  with  systemic  prednisolone  alone  and  patients
in  the  combined  treatment  group  received  three  additional
IT-DEX  injections  within  ﬁve  days.  The  main  outcome  meas-
ures  used  were  the  differences  between  pre-treatment
and  post-treatment  PTA  and  SDS.  Successful  treatment  was
deﬁned  as  a  greater  than  10  dB  improvement  in  PTA  and
15%  in  SDS.  Audiometric  evaluation  was  performed  regularly
every  other  day  during  admission,  and  subsequently  once
a  month  after  the  discharge.  The  ﬁnal  assessment  of  the
patients  in  both  groups  was  performed  three  months  after
the  completion  of  treatment.31
In  2013,  Bae  et  al.  compared  the  therapeutic  efﬁcacy  of
intratympanic  steroid  therapy  (IT-S)  and  combined  therapy
with  SS  therapy  and  IT-S  in  735  patients.  The  patients  were
divided  into  three  groups:  94  in  the  IT-S  group,  444  in  the
SS  therapy  group,  and  197  in  the  combined  therapy  group
(SS  plus  IT-S).  Hearing  was  evaluated  by  PTA  before  initial
treatment  and  at  four  weeks  following  the  ﬁnal  treatment.  A
decrease  of  more  than  10  dB  in  average  air  conduction  hear-
ing  threshold  at  0.5,  1,  2,  and  3  kHz  was  deﬁned  as  improved
hearing.  No  difference  in  the  level  of  hearing  gain  or  ratio  of
hearing  improvement  was  observed  among  the  three  groups.
IT-S  was  as  effective  as  SS  therapy  or  combined  therapy
and  could  be  considered  a  ﬁrst-line  therapeutic  modality
for  SHL.  Due  to  its  known  safety  and  efﬁcacy,  IT-S  should  be
particularly  suitable  for  patients  with  SHL  who  have  chronic
diseases  such  as  diabetes  mellitus,  hypertension,  or  chronic
renal  failure.32
Some  studies  have  shown  beneﬁts  in  combined  therapy,
especially  for  patients  with  moderate  to  severe  hearing  loss,
while  others  found  no  difference.
ConclusionIntratympanic  corticosteroid  therapy  is  prescribed  primarily
when  there  is  failure  of  conventional  therapy  or  when  use  of
systemic  corticosteroids  is  limited,  such  in  diabetic  patients.
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Based  on  these  results,  there  is  still  need  for  more
rospective  studies  with  control  groups  and  standardization
f  treatment  for  comparison  of  the  data  obtained  and  appli-
ability  of  the  proposed  therapy,  as  well  as  audiological
ollow-up  through  acoustic  and  electrophysiological  meth-
ds.
Intratympanic  corticosteroid  therapy  is indicated  espe-
ially  when  there  is  failure  of  conventional  therapy  and  when
he  use  of  systemic  corticosteroids  should  be  avoided.
onﬂicts of interest
he  authors  declare  no  conﬂicts  of  interest.
eferences
1. Benjamin ES, Charlotte A, Dorian OH, Luxon LM. Sudden sen-
sorineural hearing loss. Lancet. 2010;375:1203--11.
2. Maia RA, Cahali S. Surdez súbita. Braz J Otorhinolaryngol.
2004;70:238--48.
3. Penido NO, Ramos HVL, Barros FA, Cruz OLM, Toledo RN. Clin-
ical and etiological factors and evolution of hearing in sudden
deafness. Braz J Otorhinolaryngol. 2005;71:633--8.
4. Rauch SD, Halpin CF, Antonielle PJ, Babu S, Carey JP, Gantz BJ,
et al. Oral vs intratympanic corticosteroid therapy for idiopathic
sudden sensorineural hearing loss. JAMA. 2011;305:2071--9.
5. Raymundo IT, Bahmad F Jr, Barros Filho J, Pinheiro TG, Maia
NA, Oliveira CA. Intratympanic methylprednisolone as rescue
therapy in sudden sensorineural hearing loss. Braz J Otorhino-
laryngol. 2010;76:499--509.
6. Lee JB, Choi SJ, Park K, Park HY, Choo OS, Choung YH.
The efﬁciency of intratympanic dexamethasone injection as a
sequential treatment after initial systemic steroid therapy for
sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol.
2011;268:833--9.
7. Kakehata S, Sasaki A, Futai K, Kitani R, Shinkawa H. Daily
short-term intratympanic dexamethasone treatment alone as
an initial or salvage treatment for idiopathic sudden sensorineu-
ral hearing loss. Audiol Neurootol. 2011;16:191--7.
8. Dallan I, Bruschini L, Nacci A, Bruschini P, Traino C, Rognini F,
et al. Transtympanic steroids as a salvage therapy in sudden
hearing loss: preliminary results. ORL J Otorhinolaryngol Relat
Spec. 2006;68:247--52.
9. Plontke S, Löwenheim H, Preyer S, Leins P, Dietz K, Koitschev
A, et al. Outcomes research analysis of continuous intratym-
panic glucocorticoid delivery in patients with acute severe to
profound hearing loss: basis for planning randomized controlled
trials. Acta Otolaryngol. 2005;125:830--9.
0. Choung YH, Park K, Shin YR, Cho MJ. Intratympanic dexametha-
sone injection for refractory sudden sensorineural hearing loss.
Laryngoscope. 2006;116:747--52.
1. Chen Y, Wen L, Hu P, Qiu J, Lu L, Qiao L. Endoscopic intratym-
panic methylprednisolone injection for treatment of refractory
sudden sensorineural hearing loss and one case in pregnancy. J
Otolaryngol Head Neck Surg. 2010;39:640--5.
2. She W,  Dai Y, Du X, Yu C, Chen F, Wang J, et al. Hearing
evaluation of intratympanic methylprednisolone perfusion for
refractory sudden sensorineural hearing loss. Otolaryngol Head
Neck Surg. 2010;142:266--71.
3. Moon IS, Lee JD, Kim J, Hong SJ, Lee WS. Intratympanic dexa-
methasone is an effective method as a salvage treatment in
refractory sudden hearing loss. Otol Neurotol. 2011;32:1432--6.
4. Barreto MA, Silva IB, Oliveira CA, Bahmad F Jr. Intratympanic
corticotherapy and tinnitus control after sudden hearing loss.
Int Tinnitus J. 2012;17:186--93.
31
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
364  
5. Wang CT, Chou HW, Fang KM, Lai MS, Cheng PW. Treatment
outcome of additional dextran to corticosteroid therapy on
sudden deafness: propensity score-matched cohort analysis.
Otolaryngol Head Neck Surg. 2012;147:1125--30.
6. Chou YF, Chen PR, Kuo IJ, Yu SH, Wen YH, Wu HP. Com-
parison of intermittent intratympanic steroid injection and
near-continual transtympanic steroid perfusion as salvage
treatments for sudden sensorineural hearing loss. Laryngo-
scope. 2013;123:2264--9.
7. Xenellis J, Papadimitriou N, Nikolopoulos T, Maragoudakis P,
Segas J, Tzagaroulakis A, et al. Intratympanic steroid treatment
in idiopathic sudden sensorineural hearing loss: a control study.
Otolaryngol Head Neck Surg. 2006;134:940--5.
8. Kakehata S, Sasaki A, Oji K, Futai K, Ota S, Makinae K, et al.
Comparison of intratympanic and intravenous dexamethasone
treatment on sudden sensorineural hearing loss with diabetes.
Otol Neurotol. 2006;27:604--8.
9. Plaza G, Herráiz C. Intratympanic steroids for treatment
of sudden hearing loss after failure of intravenous therapy.
Otolaryngol Head Neck Surg. 2007;137:74--8.
0. Plontke SK, Löwenheim H, Mertens J, Engel C, Meisner C, Weid-
ner A, et al. Randomized, double blind, placebo controlled trial
on the safety and efﬁcacy of continuous intratympanic dexa-
methasone delivered via a round window catheter for severe
to profound sudden idiopathic sensorineural hearing loss after
failure of systemic therapy. Laryngoscope. 2009;119:359--69.
1. Dallan I, De Vito A, Fattori B, Casani AP, Panicucci E, Berrettini
S, et al. Intratympanic methylprednisolone in refractory sud-
den hearing loss: a 27-patient case series with univariate and
multivariate analysis. Otol Neurotol. 2010;31:25--30.
2. Li P, Zeng XL, Ye J, Yang QT, Zhang GH, Li Y. Intratympanic
methylprednisolone improves hearing function in refractory
sudden sensorineural hearing loss: a control study. Audiol Neu-
rootol. 2011;16:198--202.
3. Banerjee A, Parnes LS. Intratympanic corticosteroids for sud-
den idiopathic sensorineural hearing loss. Otol Neurotol.
2005;26:878--81.Barreto  MASC  et  al.
4. Filipo R, Covelli E, Balsamo G, Attanasio G. Intratympanic pred-
nisolone therapy for sudden sensorineural hearing loss: a new
protocol. Acta Otolaryngol. 2010;130:1209--13.
5. Zhang Q, Song H, Peng H, Yang X, Zhou J, Huang W.
Noninvasive intratympanic dexamethasone treatment for sud-
den sensorineural hearing loss. Acta Otolaryngol. 2012;132:
583--9.
6. Filipo R, Attanasio G, Russo FY, Viccaro M, Mancini P, Covelli E.
Intratympanic steroid therapy in moderate sudden hearing loss:
a randomized, triple-blind, placebo-controlled trial. Laryngo-
scope. 2013;123:774--8.
7. Gouveris H, Schuler-Schmidt W,  Mewes T, Mann W. Intratym-
panic dexamethasone/hyaluronic acid mix as an adjunct to
intravenous steroid and vasoactive treatment in patients with
severe idiopathic sudden sensorineural hearing loss. Otol Neu-
rotol. 2011;32:756--60.
8. Arslan N, Og˘uz H, Demirci M, S¸afak MA, I˙slam A, Kaytez SK,
et al. Combined intratympanic and systemic use of steroids
for idiopathic sudden sensorineural hearing loss. Otol Neurotol.
2011;32:393--7.
9. Baysal E, Tunc¸  O, Baglam T, Durucu C, Oz A, Karatas ZA, et al.
Systemic steroid versus combined systemic and intratympanic
steroid treatment for sudden sensorineural hearing loss. J Cran-
iofac Surg. 2013;24:432--4.
0. Gundogan O, Pinar E, Imre A, Ozturkcan S, Cokmez O, Yigiter
AC. Therapeutic efﬁcacy of the combination of intratym-
panic methylprednisolone and oral steroid for idiopathic
sudden deafness. Otolaryngol Head Neck Surg. 2013;149:
753--8.
1. Koltsidopoulos P, Bibas A, Sismanis A, Tzonou A, Seggas I.
Intratympanic and systemic steroids for sudden hearing loss.
Otol Neurotol. 2013;34:771--6.
2. Bae SC, Noh HI, Jun BC, Jeon EJ, Seo JH, Park SY, et al.
Efﬁcacy of intratympanic steroid therapy for idiopathic sud-
den sensorineural hearing loss: comparison with systemic
steroid therapy and combined therapy. Acta Otolaryngol.
2013;133:428--33.
